<DOC>
	<DOCNO>NCT00874978</DOCNO>
	<brief_summary>The purpose study evaluate efficacy lenalidomide treatment achieve haematopoietic improvement subject low- intermediate-1 risk International Prognostic Scoring System1 ( IPSS ) myelodysplastic syndrome ( MDS ) associate del ( 5q31-33 ) cytogenetic abnormality .</brief_summary>
	<brief_title>The Efficacy Safety Lenalidomide Monotherapy Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome ( MDS ) Associated With Del ( 5q ) Abnormality</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Understand voluntarily sign informed consent form . 2 . Age equal 18 year time signing informed consent form . 3 . Able adhere study visit schedule protocol requirement . 4 . Diagnosis low intermediate1risk ( IPSS ) MDS associate del ( 5q ) cytogenetic abnormality . The cytogenetic abnormality chromosome 5 must involve deletion band q31 q33 . The del ( 5q ) cytogenetic abnormality may isolate finding may associate cytogenetic abnormality . 5 . RBC transfusiondependent anaemia define transfusion free interval &lt; 56 consecutive day within past 112 day . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 . 7 . Women childbearing potential ( WCBP ) â€  must negative serum urine pregnancy test sensitivity least 50 mIU/mL 10 14 day prior therapy repeat within 24 hour start study drug must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 4 week start take lenalidomide . Women must also agree ongoing pregnancy test . Men must agree father child agree use condom partner child bear potential . 8 . Laboratory test result within range : Absolute neutrophil count equal 0.5 x 109/L Platelet count equal 25 x 109/L Serum creatinine equal 2.0 mg/dl Total bilirubin equal 1.5 mg/dl AST ( SGOT ) ALT ( SGPT ) equal 3 x ULN . 9 . Disease free prior malignancy equal 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` insitu '' cervix breast . 1 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 2 . Pregnant lactating female . 3 . Prior &gt; grade 3 ( National Cancer Institute [ NCI ] Common Toxicity Criteria [ CTC ] ) allergic reaction thalidomide . 4 . Prior &gt; grade 3 ( NCI CTC ) rash desquamation ( blister ) take thalidomide . 5 . Clinically significant anaemia due factor iron , B12 folate deficiency , autoimmune hereditary haemolysis gastrointestinal bleeding ( marrow aspirate evaluable storage iron , transferrin saturation must &gt; 20 % serum ferritin le 50 ng/ml ) . 6 . Use haematopoietic growth factor within 7 day first day study drug treatment . Use GCSF permit . 7 . Concurrent use erythropoietin 8 . Chronic use ( &gt; 2 week ) great physiologic dos corticosteroid agent ( dose equivalent &gt; 10 mg/day prednisolone ) within 28 day first day study lenalidomide treatment . 9 . Use experimental standard drug ( i.e . chemotherapeutic , immunosuppressive , cytoprotective agent ) treatment MDS within 28 day first day study lenalidomide treatment . 10 . Prior history malignancy MDS ( except basal cell squamous cell carcinoma carcinoma situ cervix breast ) unless subject free disease &gt; 3 year . 11 . Any prior use lenalidomide . 12 . Concurrent use anticancer agent treatment . Patients must receive form chemotherapy least 4 week prior study entry must fully recover haematological toxicity associate therapy . 13 . Known positive HIV infectious hepatitis , type A , B C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Lenalidomide</keyword>
	<keyword>myelodysplastic syndrome</keyword>
</DOC>